文献速递肝胆胰外科

离体肝切除与自体肝移植:是否应更频繁使用?

Ex Vivo Liver Resection and Autotransplantation: Should It be Used More Frequently?
PubMed 文献 · Ann Surg · 2022-08-02

本文基于美国最大宗离体肝切除经验(35例,1997–2021年),主张对部分不可切除肝肿瘤更广泛地应用该技术。所有患者均行全肝切除、低温台下血管重建与切除、部分肝自体移植。总体1/3/5年生存率为67%/39%/28%,中位生存710天,作者认为在部分肝移植经验丰富的中心可更宽松地使用该技术。

要点

  • 离体肝切除适用于部分不可切除肝肿瘤,在部分肝移植经验丰富的中心可考虑更广泛使用。
  • 35例患者总体1/3/5年生存率为67%/39%/28%,中位生存710天。
  • 高度侵袭性、中度侵袭性和低级别肿瘤的生存差异明显,低级别肿瘤预后最佳。

核心结论

  • 离体肝切除利用部分肝移植常用技术,在经验丰富的中心可相对安全地用于选择性不可切除肝肿瘤患者,作者主张更广泛地应用。

研究设计与样本

  • 回顾性分析1997至2021年间由至少完成4例离体肝切除的手术团队实施的35例离体肝切除与自体肝移植病例。

主要发现

  • 所有患者均行全肝切除、低温台下血管重建与切除、部分肝自体移植。
  • 总体1/3/5年生存率分别为67%/39%/28%,中位生存710天(范围22–4824天)。
  • 高度侵袭性肿瘤(n=18)1/3/5年生存率为61%/33%/23%,中位生存577天(范围22–3873天)。
  • 中度侵袭性肿瘤(n=14)1/3/5年生存率为67%/40%/22%,中位生存444天(范围22–4824天)。
  • 低级别肿瘤(n=3)1/3/5年生存率均为100%,中位生存1825天(范围868–3549天)。

临床怎么用

  • 在部分肝移植经验丰富的中心,对经过选择的不可切除肝肿瘤患者可考虑离体肝切除与自体肝移植。

局限性

  • 回顾性设计,样本量有限(35例),来自少数经验丰富的手术团队,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We herein advocate for more extensive utilization of ex vivo resection techniques for otherwise unresectable liver tumors by presenting the largest collective American experience. BACKGROUND: Advanced in situ resection and vascular reconstruction techniques have made R0 resection possible for otherwise unresectable liver tumors. Ex vivo liver resection may further expand the limits of resectability but remains underutilized due to concerns about technical complexity and vascular thrombosis. However, we believe that the skillset required for ex vivo liver resection is more widespread and the complications less severe than widely assumed, making ex vivo resection a more attractive option in selected case. METHODS: We retrospectively analyzed 35 cases performed by surgical teams experienced with ex vivo liver resections (at least 4 cases) between 1997 and 2021. RESULTS: We categorized malignancies as highly aggressive (n=18), moderately aggressive (n=14), and low grade (n=3). All patients underwent total hepatectomy, vascular reconstruction and resection in hypothermia on the backtable, and partial liver autotransplantation. Overall survival was 67%/39%/28%, at 1/3/5 years, respectively, with a median survival of 710 days (range: 22-4824). Patient survival for highly aggressive, moderately aggressive, and low-grade tumors was 61%/33%/23%, 67%/40%/22%, and 100%/100%/100% at 1/3/5 years, respectively, with median survival 577 days (range: 22-3873), 444 days (range: 22-4824), and 1825 days (range: 868-3549). CONCLUSIONS: Ex vivo resection utilizes techniques commonly practiced in partial liver transplantation, and we demonstrate relatively favorable outcomes in our large collective experience. Therefore, we propose that more liberal use of this technique may benefit selected patients in centers experienced with partial liver transplantation.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Weiner J, Hemming A, Levi D, et al. Ex Vivo Liver Resection and Autotransplantation: Should It be Used More Frequently? Ann Surg. 2022. PMID: 35920562. doi:10.1097/SLA.0000000000005640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。